Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy

scientific article published on 04 May 2009

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2008.21.5681
P698PubMed publication ID19414667

P50authorMorten HøyerQ61142632
P2093author name stringRolf Lewensohn
Kristina Nilsson
Giovanna Gagliardi
Jan Nyman
Karl-Axel Johansson
Christer Sederholm
Ingmar Lax
Signe Friesland
Jo-Asmund Lund
Pia Baumann
Lars Ekberg
Merete Paludan
Anders Traberg
Lena Wittgren
Elisabeth Morhed
Nina Levin
Ninni Drugge
Berit Wennberg
P433issue20
P921main subjectlung cancerQ47912
phase II clinical trialQ42824440
P304page(s)3290-3296
P577publication date2009-05-04
P1433published inJournal of Clinical OncologyQ400292
P1476titleOutcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy
P478volume27

Reverse relations

cites work (P2860)
Q38428533(Radio)biological optimization of external-beam radiotherapy
Q402719427-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Q89904623A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients
Q55071263A dosimetric comparison of three-dimensional conformal radiotherapy, volumetric-modulated arc therapy, and dynamic conformal arc therapy in the treatment of non-small cell lung cancer using stereotactic body radiotherapy.
Q48312990A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC.
Q41825343A dosimetric phantom study of dose accuracy and build-up effects using IMRT and RapidArc in stereotactic irradiation of lung tumours
Q57282826A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
Q36315106A method of dose reconstruction for moving targets compatible with dynamic treatments
Q32173730A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
Q26801050A review of stereotactic body radiotherapy - is volumetric modulated arc therapy the answer?
Q36119520A review of update clinical results of carbon ion radiotherapy
Q93347944A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer
Q38790915A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer
Q29248448A treatment-planning comparison of three beam arrangement strategies for stereotactic body radiation therapy for centrally located lung tumors using volumetric-modulated arc therapy
Q92281611Adoption of Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer Across the United States
Q52723380Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer.
Q35200640Alternative to surgery in early stage NSCLC-interventional radiologic approaches
Q34337294American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer
Q87410539Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors
Q64269417Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)
Q55251898Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis.
Q26823670Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?
Q31152462Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT
Q43042909CT-guided (125)I brachytherapy on pulmonary metastases after resection of colorectal cancer: A report of six cases
Q64964699Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
Q36599965Carbon ion radiotherapy for oligo-recurrence in the lung
Q53914428Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
Q27301421Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
Q28083924Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?
Q99240991Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review
Q38663392Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy
Q53525161Clinical characteristics and outcome of pneumothorax after stereotactic body radiotherapy for lung tumors.
Q35824272Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer
Q30570350Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases.
Q59125770Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer
Q47103518Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases
Q49356303Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases
Q37691881Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer
Q36101987Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence
Q34202715Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
Q34663557Colorectal hepatic metastasis: Evolving therapies
Q91700135Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy
Q44946517Commissioning and initial stereotactic ablative radiotherapy experience with Vero
Q98178313Common Error Pathways in CyberKnife™ Radiation Therapy
Q38685007Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy.
Q64236584Comparing phase- and amplitude-gated volumetric modulated arc therapy for stereotactic body radiation therapy using 3D printed lung phantom
Q47446694Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
Q90136503Comparison of Three Radiobiological Models in Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer
Q36382039Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis
Q38914996Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis.
Q38240581Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller
Q42116312Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response
Q34331400CyberKnife for hilar lung tumors: report of clinical response and toxicity
Q33698367CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment
Q53083823DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer.
Q37468265Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer
Q41857918Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon.
Q36661346Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer
Q36100808Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer?
Q30421587Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer
Q36279626Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer
Q93185154Dosimetric comparison of different algorithms in stereotactic body radiation therapy (SBRT) plan for non-small cell lung cancer (NSCLC)
Q42150664Dosimetric comparison of three-dimensional conformal radiotherapy, intensity modulated radiotherapy, and helical tomotherapy for lung stereotactic body radiotherapy
Q37789035Early detection and screening of lung cancer
Q64081214Editorial on comparison between stereotactic body radiotherapy and surgery in early stage NCSLC by Scotti
Q47826009Effects of collimator angle, couch angle, and starting phase on motion-tracking dynamic conformal arc therapy (4D DCAT).
Q41909998Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer
Q27015651Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice
Q37645201Emerging treatment options in the management of non-small cell lung cancer.
Q48010740Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients
Q37090175Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution
Q58760175Evaluation of delivered dose to a moving target by 4D dose reconstruction in gated volumetric modulated arc therapy
Q41887780Evaluation of heterogeneity dose distributions for Stereotactic Radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms
Q37670422Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy
Q37151785Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree
Q57058757Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)
Q55110451Flattening filter-free technique in volumetric modulated arc therapy for lung stereotactic body radiotherapy: A clinical comparison with the flattening filter technique.
Q47142210Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer
Q83182085High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer
Q90115551Hypofractionated 192Ir source stereotactic ablative brachytherapy with coplanar template assistance in the primary treatment of peripheral lung cancer
Q90160118Hypofractionated carbon-ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study
Q36840379Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer
Q52716524Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience.
Q41773467Image-guided radiation therapy: Physician's perspectives
Q35663626Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer: Evaluation of mass-like fibrosis
Q91868558Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors
Q33639144Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates
Q37301068Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy
Q38705654Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
Q47141026Institutional experience on the treatment of lung and liver lesions with stereotactic body radiotherapy and Novalis Exactrac Adaptive Gating technique
Q36621168Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer
Q38051243Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery?
Q42108214Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?
Q38233871Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?
Q41856048Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy
Q38705115Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy
Q64997326Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.
Q50862063Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Q47149089Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer
Q37698823Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry
Q47098433Lung reirradiation with stereotactic body radiotherapy
Q61815135Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series
Q47102090Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam technique: a comparison of clinical outcomes
Q84632256Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment
Q36235727LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective
Q88149109Management of Lung Cancer in the Elderly
Q48961059Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery
Q64099332Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy
Q61804649Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes
Q36382553Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
Q39186802Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: A review from NRG oncology
Q64080735Multiple primary lung cancer: a rising challenge
Q39369140Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Q33758565No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236
Q50518699No differences in radiological changes after 3D conformal vs VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer.
Q36803114Non-small cell lung cancer therapy: safety and efficacy in the elderly
Q35971331Non-small cell lung cancer: the challenges of the next decade
Q37874768Non-small-cell lung cancer.
Q42157461Oligometastatic disease, the curative challenge in radiation oncology
Q35880933Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer.
Q35592628Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer
Q38907646PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
Q42154657Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution
Q64267035Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer
Q47651774Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer.
Q38021143Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis
Q48202266Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1).
Q64277127Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer
Q53112046Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.
Q55128287Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT).
Q56528378Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?
Q61804645Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy
Q47110081Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non-small-cell lung cancer
Q26851601Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients
Q87460952Primary non-small cell lung cancer in a transplanted lung treated with stereotactic body radiation therapy. A case study
Q36524133Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis
Q47735759Prospective evaluation of anxiety, depression and quality of life in medically inoperable early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy.
Q30416741Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary
Q47142130Quality and safety in stereotactic radiosurgery and stereotactic body radiation therapy: can more be done?
Q35180568Quality of life and symptoms following stereotactic body radiotherapy in early-stage lung cancer patients
Q92040126Questionnaire survey on treatment planning techniques for lung stereotactic body radiotherapy in Japan
Q37007890Radiation therapy for early stage lung cancer
Q26765355Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Q36363955Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy
Q37458027Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer
Q33787072Radiofrequency ablation for early-stage nonsmall cell lung cancer
Q47095312Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC).
Q94592974Radiotherapy in Lung Cancer: Current and Future Role
Q57875955Radiothérapie en conditions stéréotaxiques des patients inopérables
Q58804832Reirradiation for locoregionally recurrent non-small cell lung cancer
Q35835107Relative clinical effectiveness of carbon ion radiotherapy: theoretical modelling for H&N tumours.
Q55119541Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy.
Q38802618Risk factors and management of oligometastatic non-small cell lung cancer
Q35907834Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection
Q37566614Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
Q36493928SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD.
Q35200592SBRT in operable early stage lung cancer patients.
Q42384628SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation
Q98771302Significant Correlation Between Overall Survival and Mean Lung Dose in Lung Stereotactic Body Radiation Therapy (SBRT)
Q38871523Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies
Q41946577Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
Q91742496Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review
Q42079167Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
Q56523398Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial
Q64248763Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
Q53062109Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage I Non–Small-Cell Lung Cancer: A Markov Model–Based Decision Analysis
Q49310050Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis.
Q36286591Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
Q41112569Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard
Q84443095Stereotactic ablative radiotherapy for inoperable stage I NSCLC
Q35667829Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies
Q37179433Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer
Q41834552Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes
Q47159050Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes
Q57172947Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances
Q42857993Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes
Q36550532Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity
Q57177641Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions
Q34368868Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience
Q36555959Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis.
Q64096283Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications
Q34859171Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
Q37649474Stereotactic body radiation therapy: a novel treatment modality
Q38560967Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients
Q90481023Stereotactic body radiotherapy feasibility for patients with peripheral stage I lung cancer and poor pulmonary function
Q58788717Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the "no fly" zone
Q53054421Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.
Q46159777Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis
Q38155155Stereotactic body radiotherapy for early stage lung cancer
Q35143839Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry
Q89870886Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer
Q42033188Stereotactic body radiotherapy for small lung tumors in the University of Tokyo Hospital
Q49356651Stereotactic body radiotherapy for stage I non-small cell lung cancer
Q41273661Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
Q33813917Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer
Q93069239Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer
Q82084588Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study
Q36734816Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer
Q90591596Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer
Q38175120Stereotactic body radiotherapy: a critical review for nonradiation oncologists
Q28076058Stereotactic body radiotherapy: current strategies and future development
Q35824255Stereotactic radiotherapy for early stage non-small cell lung cancer
Q38367507Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?
Q48369218Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.
Q36644220The effect of beam arrangements and the impact of non-coplanar beams on the treatment planning of stereotactic ablative radiation therapy for early stage lung cancer
Q34366525The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer
Q47734152The impact of technology on the changing practice of lung SBRT.
Q38224998The role of percutaneous image-guided ablation for lung tumors
Q64120986The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
Q27000405Thermal ablation of malignant lung tumors
Q37066702Toward a planning scheme for emission guided radiation therapy (EGRT): FDG based tumor tracking in a metastatic breast cancer patient
Q36835347Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT).
Q42098921Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability
Q55350018Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy.
Q26853124Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy?
Q58584561Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy
Q39015830Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.
Q43112508Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study
Q38084619Volume Modulated Arc Therapy (VMAT) for pulmonary Stereotactic Body Radiotherapy (SBRT) in patients with lesions in close approximation to the chest wall
Q40342856What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer?
Q38172228What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer
Q92467682Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate
Q89921619[Minimally Invasive Therapies For Early Stage Non-Small Cell Lung Cancer]

Search more.